Radiotracers provide molecular- and cellular-level information in a noninvasive manner and have become important tools for precision medicine. In particular, the successful clinical application of radioligand therapeutic (RLT) has further strengthened the role of nuclear medicine in clinical treatment. The complicated microenvironment of the lesion has rendered traditional single-targeted radiopharmaceuticals incapable of fully meeting the requirements. The design and development of dual-targeted and multitargeted radiopharmaceuticals have rapidly emerged. In recent years, significant progress has been made in the development of heterologous dual-targeted radiopharmaceuticals. This perspective aims to provide a comprehensive overview of the recent progress in these heterologous dual-targeted radiopharmaceuticals, with a special focus on the design of ligand structures, pharmacological properties, and preclinical and clinical evaluation. Furthermore, future directions are discussed from this perspective.

中文翻译：

---

具有异源双靶点功能的新型放射性药物的现状和展望（2013-2023 年）


放射性示踪剂以无创方式提供分子和细胞水平的信息，已成为精准医疗的重要工具。特别是放射配体治疗 （RLT） 的成功临床应用进一步加强了核医学在临床治疗中的作用。病灶复杂的微环境使得传统的单靶点放射性药物无法完全满足要求。双靶点和多靶点放射性药物的设计和开发已经迅速出现。近年来，异源双靶点放射性药物的开发取得了重大进展。本观点旨在全面概述这些异源双靶点放射性药物的最新进展，特别关注配体结构的设计、药理学特性以及临床前和临床评估。此外，从这个角度讨论了未来的方向。